Research Progress of Carrier-Free Antitumor Nanoparticles Based on Phytochemicals

Siliang Jiang1†, Yu Fu1†, Xinyang Zhang2, Tong Yu1, Bowen Lu1 and Juan Du1*

1Department of Pharmacognosy, College of Pharmacy, Jiamusi University, Jiamusi, China, 2School of Clinical Medicine, Jiamusi University, Jiamusi, China

Cancer is a major worldwide public health issue, responsible for millions of deaths every year. Cancer cases and deaths are expected to increase rapidly with population growth, age, and lifestyle behaviors that increase cancer risk. Long-term chemotherapy results in acquired drug resistance. Traditional treatment methods have limitations and cannot effectively treat distant metastatic cancers. Application of nanocarriers in multi-chemotherapy must be promoted. With research progress, the shortcomings of traditional nanocarriers have gradually become evident. Carrier-free nanodrugs with desirable bioactivity have attracted considerable attention. In this review, we provide an overview of recent reports on several carrier-free nanodrug delivery systems based on phytochemicals. This review focuses on the advantages of carrier-free nanodrugs, and provides new insights for establishment of ideal cancer treatment nanosystems.

Keywords: cancer, carrier-free, nanodrug, phytochemicals, self-assembly

INTRODUCTION

Cancer is a major worldwide public health issue, causing millions of deaths every year (Siegel et al., 2021). Cancer cases and deaths are expected to increase rapidly with population growth, age growth, and lifestyle behaviors that increase cancer risk (Torre et al., 2016). It is estimated that by 2040, the global cancer burden will nearly double (29–37 million), which will have a significant impact on lower middle-income countries (More et al., 2021). Scientists and doctors have made great research efforts to develop efficient and powerful cancer therapies, including surgery, drug therapy, and radiotherapy (Hashizume and Tsugawa, 2004; Pérez-Herrero and Fernández-Medarde, 2015; Allen et al., 2017). These treatments have their own advantages and disadvantages. Surgical treatment is the first choice for local solid tumors, but its limitations with distal metastatic tumors are obvious (Klein, 2020). With radiotherapy, healthy cells become target cells and are destroyed, resulting in drastic changes in the internal cell environment. Thus, antitumor drugs with curative effects on solid tumors and distant metastases are irreplaceable in cancer treatment. Currently available commercial antitumor drugs can be classified as synthetic drugs or natural drugs. Synthetic drugs are usually the only choice for cancer chemotherapy, but there are problems with drug safety, toxicity, and side effects (Chang et al., 2011). According to the mechanism of action, commonly used chemotherapeutic drugs can be divided into several categories including antimetabolites, alkylating agents, and mitotic spindle inhibitors (Tiwari, 2012; Singh et al., 2018). Gemcitabine (GEM) is a first-line chemotherapeutic drug for pancreatic cancer. However, its curative effect is unsatisfactory. GEM has a short blood circulation time and is dispersed into normal tissues, leading to severe side effects such as nausea and myelosuppression. Moreover, poor uptake, short half-life, and low bioavailability of gem cells

Edited by: Xing Wang, Institute of Chemistry (CAS), China
Reviewed by: Xiuli Zhao, Shenyang Pharmaceutical University, China; Hailing Xin, Second Military Medical University, China; Lin Zhang, Dalian Medical University, China

*Correspondence: Juan Du jmsdujuan@126.com
† These authors have contributed equally to this work

Specialty section: This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology

Received: 22 October 2021
Accepted: 29 November 2021
Published: 08 December 2021

Citation: Jiang S, Fu Y, Zhang X, Yu T, Lu B and Du J (2021) Research Progress of Carrier-Free Antitumor Nanoparticles Based on Phytochemicals. Front. Bioeng. Biotechnol. 9:799806. doi: 10.3389/fbioe.2021.799806

Frontiers in Bioengineering and Biotechnology | www.frontiersin.org December 2021 | Volume 9 | Article 799806
require frequent high-dose administration, resulting in severe systemic toxicity (Li et al., 2020c; Takemoto et al., 2020).

Multidrug resistance (MDR) is the main refractory to chemotherapy, defined as the resistance of cancer cells to multiple chemotherapeutic drugs with different structures and mechanisms of action (Li et al., 2017). This obstacle is particularly important because the treatment window for most anticancer drugs is relatively narrow, with a small difference between the dose required to achieve a therapeutic effect and to cause toxicity (Assaraf et al., 2019). MDR can be caused by several mechanisms: decreased uptake of water-soluble drugs; changes in cells that affect the ability of cytotoxic drugs to kill cells, including changes in cell-cycle checkpoints and blocks, an increase in DNA damage repair, a decrease in apoptosis, and changes in drug metabolism; sequestration of anticancer drugs in lysosomes and in intracellular organelles and intercellular vesicles (Szakacs et al., 2006; Li et al., 2016). MDR is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutics or novel targeted drugs (Bukowski et al., 2020). According to the biochemical changes in malignant cells, the mechanism of cellular resistance can be divided into non-classical MDR phenotypes and transport-based classical MDR phenotypes (Stavrovskaya, 2000). Non-classical MDR describes non-transport-based mechanisms and includes altered enzyme activity of glutathione S-transferase (GST) and topoisomerase, which can decrease the cytotoxic activity of drugs and changes in the balance of proteins involved in apoptosis (Kartal-Yandim et al., 2016). The classical mechanism targets anticancer drug transport across the cell membrane by increasing the activity of efflux pumps such as adenosine triphosphate (ATP)-binding cassette (ABC) transporters (Liu et al., 2020) to increase the efflux of anticancer drugs through membrane-embedded drug transporters. Membrane-embedded drug transporters are usually overexpressed in cancer cells; recent studies have found that they can be regulated by endogenous cytokines (Kumar and Jaitak, 2019). Although recent studies have explored autophagy to hijack MDR cancer cells in anticancer treatment, the mechanism of the relationship between autophagy and MDR has not been fully studied (Li et al., 2017). Thus, the trend is to use safe natural drugs with tumor growth inhibitory activity that target a variety of cellular pathways in cancer cells with no toxicity to normal cells.

For thousands of years, traditional herbal medicines have provided natural treatment of cancer and many diseases; the discovery of antitumor drugs mainly results from screening of natural products and their analogues (Chang et al., 2011; Salminen et al., 2018). In recent decades, botanical drugs have been widely used in cancer treatment, providing an alternative to traditional treatment with no harmful effects. Although phytochemicals have demonstrated great potential as anticancer agents, many problems remain to be considered. Oral administration of plant preparations may have a first-pass effect and eventually degrade. For example, although curcumin has shown good prospects for cancer treatment, its clinical development is limited due to its low bioavailability and low aqueous solubility. In clinical trials, orally administered curcumin (8 g/day) is rapidly converted into metabolites, resulting in a low level of free curcumin in plasma (<2.5 ng/ml) (Giordano and Tommonaro, 2019). The emergence of drug resistance involving multiple mechanisms is the main obstacle to successful clinical application of phytochemicals as therapeutic cancer drugs. Another obstacle to the use of phytochemicals in clinical practice is the development of MDR (Rizwanullah et al., 2018). The disadvantages of plant compounds such as low aqueous solubility, poor cell permeability, hepatic disposition, narrow therapeutic index, and rapid absorption in normal tissues limit their application (Siddiqui and Mukhtar, 2010). To meet these challenges, the scientific community has turned to the delivery of phytochemicals based on nanodrugs as they can improve water solubility and bioavailability, target specific tumor cell tissues, improve cell uptake, reduce phytochemical dosage, and achieve a stable therapeutic phytochemical level (Dombe and Shirote, 2021; Kim et al., 2021). Although nanotechnology-based drug delivery systems have great potential in cancer treatment, there are still many issues, including low drug encapsulation efficiency and cumulative deposition of nanomaterials in vivo. Carrier components usually account for the majority of these nanosystems (Ding et al., 2020). The drug-loading efficiency of anticancer drugs is still very low, and long-term toxicity remains unclear. Use of a large number of carrier drugs to achieve an effective dose leads to low drug-loading and high carrier uptake (Ma et al., 2014; Karaosmanoglu et al., 2021).

Carrier-free nanodrugs used for drug delivery are mainly self-assembled by prodrugs, pure drugs, or amphiphilic drug-drug conjugates. They generally have low systemic toxicity, high drug-loading capability, stimulus-sensitive features, and synergistic therapeutic efficacy (Mei et al., 2022). Recent studies have shown that phytochemicals can form carrier-free nanodrugs through self-assembly. Self-assembly technology can overcome the limitations of phytochemicals in application (Sun et al., 2019; Li et al., 2020a). Phytochemical self-assembled nanodrugs have the following advantages: no carrier; less toxicity and side effects; good drug-loading capacity and pharmacokinetics; MDR inhibition; therapeutic synergy. As an emerging field, research is still in progress. Based on the great progress of carrier-free nanodrugs in cancer treatment, most recent reviews have summarized the preparation, application, and significant antitumor efficiency of carrier-free nanodrugs as a combination of therapeutic agents with different antitumor mechanisms. Carrier-free drugs based on plant compounds have received less attention. In this review, carrier-free drug design based on natural products is summarized to provide a coherent overview and clear direction for the rational design of carrier-free nanodrugs.

THE PREPARATION OF CARRIER-FREE NANODRUGS

Compared with the traditional nanodrug delivery systems, the preparation method of the carrier-free nanodrugs is a simpler process, uses less or no organic solvents are introduced in the preparation process. It is generally divided into in vitro and in vivo self-assembly strategies. In vitro self-assembly strategies...
include top-down method, reverse solvent precipitation method and template assisted method (Zhang et al., 2015; Gigliobianco et al., 2018). The carrier free nanodrugs prepared by in vitro self-assembly strategy can have higher drug loading, longer blood circulation time or more effective absorption. Compared with the in vitro self-assembly strategy, the in vivo self-assembly strategy utilizes small molecules reaching the target triggered by tumor specific stimulation, which is easier to operate and does not require any high energy consuming machines or other assembly processes (Mei et al., 2022).

Carrier-free drug delivery systems can be rapidly established and used in cancer treatment because of the various attractions of carrier free drug delivery systems; first, Controllable structure, which can protect drugs and improve tumor accumulation; second, increase the drug loading; third, reduce the side effects caused by the carrier; last, simple preparation and administration of drugs (Qin et al., 2017; Shim et al., 2019). The assembly process is a spontaneous behavior of molecules in solvents, which follows the principle of minimum energy. Its essence is intermolecular force. Therefore, compounds that can form non covalent bond force between molecules can usually produce self-assembly. Drug or phytochemical molecules could self-assemble into nanoparticles under the dynamic control of noncovalent bonds, such as hydrogen bond, π-π interaction, van der Waals force, charge transfer effect, dipole-dipoles and hydrophobic interactions (Whitesides and Grzybowski, 2002; Rybtchinski, 2011; Gao et al., 2016; Yang et al., 2019). When molecules are combined by hydrogen bond, single or multiple hydrogen bond can be formed. Generally, the stronger the multiplicity of hydrogen bond, the stronger the binding energy and stability between molecules. Different organic molecules, such as biocompatible polymeric chains or endogenous molecules, have been used as self-assembly inducers by covalent linkage to drugs. The drug and the self-assembly inducer can be directly attached or can be connected by a linker, which can be stable in serum but able to release the drug intracellularly (Fumagalli et al., 2016).

CARRIER-FREE NANODRUGS BASED ON CURCUMIN

Curcumin (Cur) (Figure 1A) is a phenolic metabolite isolated from Curcuma longa (turmeric), known as diferuloylmethane (Ashrafizadeh et al., 2020; Salehi et al., 2020). The IUPAC name of curcumin is (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, with a chemical formula of C_{21}H_{20}O_{6} and a molecular weight of 368.38 (Giordano and Tommonaro, 2019). Cur has demonstrated excellent pharmacological activities, including anti-inflammatory, antioxidant, antitumor, anti-analgesic, neuroprotective, hepatoprotective, and cardioprotective activities (Shabgah et al., 2021). A review of relevant literature confirmed that Cur may have a negative effect on the development, expansion, migration, and invasion of cancer cells (Hu et al., 2018; Pricci et al., 2020; Termeni et al., 2020). Similar to other natural plant-derived compounds, curcumin has poor bioavailability, and requires the assistance of a nanodrug delivery system.

Sun et al. (Sun et al., 2019) designed a carrier-free nanodrug (Cur-NDs) based on Cur using the reprecipitation method. The process is based on the strong interaction between Cur molecules
(hydrophobic interactions and P-P stacking), allowing formation of stable nanoparticles with sizes of 60–80 nm and retaining the bioactive groups of Cur. Compared with free Cur, Cur-NDs exhibited obvious optical properties and light-sensitive drug-release behavior, resulting in an increase in ROS and photodynamic therapy on breast cancer cells. In addition, apoptosis during Cur-based photodynamic therapy is accompanied by ROS-mediated activation of the JNK/caspase-3 signaling pathway. In addition to self-assembly of Cur molecules, Cheng et al. (Cheng et al., 2020) designed carrier-free nanoparticles based on a curcumin-erlotinib conjugate (EPC), with a size of approximately 105 nm and a hydrodynamic size of 146.3 nm with a PDI of 0.157. Compared with free Cur and erlotinib, EPCs have stronger cytotoxicity and better anti-migration and anti-invasion effects on BxPC-3 pancreatic cancer cells. Benefiting from both passive and active tumor-targeting effects, EPCs effectively reduced the growth of pancreatic tumors and extended the median survival time of tumor-bearing mice from 22 to 68 days. Camptothecin (CPT) is an alkaloid with potent antitumor activity on BxPC-3 pancreatic cancer cells. Bene cytotocicity and better anti-migration and anti-invasion effects, EPCs effectively reduced the growth of pancreatic tumors and extended the median survival time of tumor-bearing mice from 22 to 68 days. Camptothecin (CPT) is an alkaloid with potent antitumor activity first found in plants. CPT analogs (irinotecan and topotecan) have been approved by the FDA for cancer treatment. A recent study designed a self-assembled ion pair complex, ICN, based on plants. CPT analogs (irinotecan and topotecan) have been shown to increase the half-life of paclitaxel and ursolic acid (UA) in nano-preparations (UA-Ptx) by self-assembly. UA-Ptx can effectively prolong the plasma half-life of paclitaxel and ursolic acid and prevent the rapid leakage of drugs in the body. UA-Ptx nanoparticles exhibit the excellent anticancer activity of Ptx, and retain the antitumor and liver-protective effects of UA, with a good synergistic effect. In addition, a novel carrier-free drug delivery system (DDS) assembled from a drug chemical gene conjugate was designed using fluorescent dithiomaleamide (DTM) as a linker to combine two Ptx molecules with floxuridine (FdU)-integrated antisense oligonucleotides (known as a chemogene) (Zhu et al., 2020). This Ptx chemical gene conjugate can be self-assembled into spherical nucleic acid (SNA)-like micellar nanoparticles as carrier-free DDS. It can effectively inhibit the expression of P-glycoprotein, and then release FDU and Ptx to exert a synergistic anticancer effect. Ptx chemical gene conjugates may help reverse MDR in cancer.

**CARRIER-FREE NANODRUGS BASED ON PACLITAXEL**

Paclitaxel (Ptx, trade name Taxol) is a well-known anticancer agent with a unique mechanism of action (Figure 1B). It is considered to be one of the most successful natural anticancer drugs (Zhu and Chen, 2019). It was approved by the US Food and Drug Administration (FDA) in 1992 for treatment of advanced ovarian cancer (Swain et al., 1995). However, as an aromatic anticancer drug that is usually insoluble in physiological solutions, severely hindering bioavailability, it requires the assistance of a drug-delivery system (Yang et al., 2021).

A recent study reported co-loaded self-assembled nanofibers (P/T-NFs) based on Ptx and tetrandrine (Tet) (Li et al., 2020b). Ptx-SA-RGD obtained by combining Ptx and the tumor-specific peptide arginine-glycine aspartate peptide (RGD) with succinic acid (SA) as a linker was used as a highly effective drug-loaded nanofiber, and encapsulated in P-NFs. Novel P/T-NFs were obtained, mainly formulated through π-π stacking and hydrophobic interactions. In vitro studies have shown that the increased cytotoxicity of P/T-NFs in cancer cells is attributed to an increased level of intracellular ROS, lower expression of p-JAK2 and p-STAT3, and promotion of mitochondrial apoptosis. In vivo studies have also confirmed the superior antitumor effect of P/T-NFs, but the mechanism must be further explored. Wang et al. (Wang et al., 2020a) used the anticancer activity and self-assembly characteristics of Ptx and ursolic acid (UA) in nano-preparations (UA-Ptx) by self-assembly. UA-Ptx can effectively prolong the plasma half-life of paclitaxel and ursolic acid and prevent the rapid leakage of drugs in the body. UA-Ptx nanoparticles exhibit the excellent anticancer activity of Ptx, and retain the antitumor and liver-protective effects of UA, with a good synergistic effect. In addition, a novel carrier-free drug delivery system (DDS) assembled from a drug chemical gene conjugate was designed using fluorescent dithiomaleamide (DTM) as a linker to combine two Ptx molecules with floxuridine (FdU)-integrated antisense oligonucleotides (known as a chemogene) (Zhu et al., 2020). This Ptx chemical gene conjugate can be self-assembled into spherical nucleic acid (SNA)-like micellar nanoparticles as carrier-free DDS. It can effectively inhibit the expression of P-glycoprotein, and then release FDU and Ptx to exert a synergistic anticancer effect. Ptx chemical gene conjugates may help reverse MDR in cancer.

**CARRIER-FREE NANODRUGS BASED ON URSCOLIC ACID**

UA, or 3-β-hydroxy-urs-12-en-28-oic acid (Figure 1C) is a pentacyclic triterpene acid that is abundant in most plants (Yin et al., 2018). Many studies have reported the potential of UA in cancer prevention and treatment; it has great impact in remodeling the tumor microenvironment and can play a direct role in cell proliferation, apoptosis, and cell cycle regulation (Chan et al., 2019; Guo et al., 2019; Khwaza et al., 2020). However, studies have reported that the average plasma concentration of UA is very low, even at high doses, indicating that the bioavailability of UA is low (Liao et al., 2005; Yin et al., 2018).

Carrier-free nanoparticles based on UA-Methotrexate (MTX) have been designed to target folate receptors; their synergistic anticancer activity has been studied in vitro and in vivo (Lan et al., 2021). The best preparation method for UA-MTX NPs is shown in Table 1. Compared with free UA or MTX, the water solubility of UA-MTX NPs was significantly improved. At pH = 5, the drug release rate of UA-MTX NPs was increased, suggesting that UA-MTX NPs can quickly release MTX in acidic tumor microenvironment conditions. In MCF-7 cells, UA-MTX NPs exhibit excellent folate receptor targeting. In MCF-7 cells overexpressing folate receptors, the antiproliferative capacity of UA-MTX NPs was greater than that of free drugs. In vivo, UA-
MTX NPs exhibit good biosafety and can improve antitumor efficacy through combined therapy. Song et al. (Song et al., 2014) formulated UA nanocrystals using the antisolvent precipitation method. The results showed that the UA nanocrystals had good aqueous dispensability and could be completely dissolved in 0.5% sodium dodecyl sulfate solution within 120 min. Moreover, the nanocrystal characteristics remained unchanged for 49 days, indicating great stability. Pi et al. (Pi et al., 2016) evaluated the bioavailability of UA nanocrystals and found that it was 2.56 times greater than that of free UA (Shao et al., 2020). Fan et al. (Fan et al., 2018) designed a carrier-free nanodrug through self-assembly of UA molecules. The process was based on the hydrogen bond and hydrophobic interactions between UA molecules. The UA NPs were nearly spherical, with a diameter of approximately 150 nm, and a drug-loading of up to 60%. UA NPs exhibited greater antiproliferative activity, significantly induced apoptosis, decreased expression of COX-2/VEGFR2/VEGFA, increased the immunostimulatory activity of TNF-α, IL-6, and IFN-β, and decreased the activity of STAT-3 in A549 cells in vitro.

**CARRIER-FREE NANODRUGS BASED ON CAMPTOTHECIN**

CPT (Figure 1D) is a DNA topoisomerase I inhibitor from the Chinese Camptotheca Acuminat tree, with excellent anticancer activity in solid tumors including primary and metastatic colon carcinoma, small-cell lung carcinoma, ovarian, breast, pancreatic, and stomach cancers. Poisoning of DNA topoisomerase I is the mechanism by which CPT interferes with tumor growth. Although clinical use of CPT has had a significant impact on cancer therapy, de novo or acquired clinical resistance to these drugs is common (Beretta et al., 2013). CPT has low bioavailability, poor water solubility, and significant side effects after injection, hindering further clinical application.

Xu et al. (Xu et al., 2018) connected gemcitabine and CPT through redox-sensitive disulfide bonds to prepare a carrier-free, reduction-degradable Janus prodrug CPT-SS-GEM. CPT-SS-GEM is amphiphilic and can be self-assembled into Janus nano-prodrugs without any excipients in water. The rapid drug release of nano-prodrugs is reduction-dependent. More than 90% of natural CPT and GEM were released in a mimicked tumor cell microenvironment (pH 6.5 PBS, containing 2 Mm DTT) within a period of 3 h. Gao et al. (Gao et al., 2020) connected CPT with Ptx through disulfide bonds to prepare a self-assembled prodrug, PTX-S-S-CPT. PTX-S-S-CPT exhibited good monodispersity, with a particle size of approximately 200 nm. Due to the redox response with a disulfide bond, the PTX-S-S-CPT prodrug NPs significantly inhibited cancer cell growth, with no obvious toxicity to healthy cells. Zhao et al. (Zhao et al., 2020) used CPT derivatives, 7-ethyl-10-hydroxycamptothecin (SN38), and chlorin e6 (Ce6) to co-assemble new carrier-free NPs (SN38/Ce6 NPs) using a simple antisolvent precipitation method. SN38/Ce6 NPs exhibited uniform morphology with a particle size of approximately 150 nm and a zeta potential of approximately −30 mV, good stability in aqueous solution and in a lyophilized state, and high cellular uptake efficiency against murine mammary carcinoma (4T1) cell lines. Wang et al. (Wang et al., 2020b) constructed a new self-assembled based on CPT and carbamoylmannose conjugates (CPT-Man). The self-assembly of CPT-Man formed nanotube components in water with dose-dependent and time-dependent cytotoxicity to MCF-7, HeLa, and A549 cells. In MCF-7 cells, CPT-Man demonstrated potent antitumor activity, with an IC50 value of 2.7 μM in 48 h, an increase of 2.2 times compared with the activity of CPT (6.1 μM).

**CONCLUSION AND FUTURE OUTLOOKS**

In this review, the latest progress in carrier-free nanodrugs based on several anticancer phytochemicals was summarized. With research advances, the advantages and versatility of carrier-free nanodrug systems for cancer treatment are gradually becoming evident. NPs based on a phytochemical self-assembly strategy use bioactive natural drug components with self-assembly characteristics as the carrier without introducing other materials, improving drug delivery efficiency, exerting drug efficacy, and reducing toxic and side effects. Self-assembled NPs of different phytochemical molecules can play a synergistic role in treatment for a variety of diseases. The properties of hydrophobic drug molecules can be easily adjusted by combining them with functional molecules to prepare nanodrugs with improved functional properties. Different self-assembly behaviors are observed based on the strength and nature of non-covalent interactions such as van der Waals forces, hydrogen bonds, and π-π stacking, resulting in different nano-assembly sizes and morphologies (Karaoğlanoglu et al., 2021). However, there are still some defects in carrier-free NPs based on self-assembly of phytochemicals. Most current NPs are limited to a combination of two drugs; there are few reports on self-assembly of more drug molecules. In addition, the self-

**TABLE 1 | Optimization of UA NPs and MTX-UA NPs (Lan et al., 2021).**

| Optimization | Methanol | Concentration of UA (mM) | Methanol/water ratio | MTX/UA ratio |
|--------------|----------|--------------------------|----------------------|--------------|
| Size (nm)    | 179.3    | 167.5                    | 143.2                | 152.6        |
| PDI          | 0.198    | 0.114                    | 0.115                | 0.164        |
| Zeta potential (mV) | —       | —                        | —                    | —            |

**TABLE 2 | Zeta potential (mV) and Size (nm) of UA NPs and MTX-UA NPs (Lan et al., 2021).**

| Optimization | Zeta potential (mV) | Size (nm) |
|--------------|---------------------|-----------|
| Methanol     | 30.6                | 179.3     |
| MTX/UA       | 48.2                | 152.6     |
assembly force between phytochemicals is based mainly on intermolecular forces; thus, the stability of NPs is poor. Further, NPs should be tuned to optimize their key properties including size, shape, and surface chemistry. Carrier-free drugs have shown promising results in overcoming MDR. However, the potential biological toxicity of carrier-free drugs has not been clinically verified; much research is needed for confirmation. The authors are optimistic that in the near future, carrier-free drugs based on phytochemistry will find a place in treatment of drug-resistant cancer.

REFERENCES

Allen, C., Her, S., and Jaffray, D. A. (2017). Radiotherapy for Cancer: Present and Future. Adv. Drug Deliv. Rev. 109, 1–2. doi:10.1016/j.addr.2017.01.004

Ashrafizadeh, M., Zarrabi, A., Hashemi, F., Moghadam, E. R., Hashemi, F., Entezari, M., et al. (2020). Curcumin in Cancer Therapy: A Novel Adjunct for Combination Chemotherapy with Paclitaxel and Alleviation of its Adverse Effects. Life Sci. 256, 117984. doi:10.1016/j.lfs.2020.117984

Assaraf, Y. G., Brozovic, A., Goncalves, A. C., Jurkovicova, D., Liné, A., Machuqueiro, M., et al. (2019). The Multi-Factorial Nature of Clinical Multidrug Resistance in Cancer. Drug Resist. Updates 46, 100645. doi:10.1016/j.drup.2019.100645

Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. IJMS 21 (9), 3233. doi:10.3390/ijms21093233

Chan, E. W. C., Soon, C. Y., Tan, J. B. L., Wong, S. K., and Hui, Y. W. (2019). Ursolic Acid: An Overview on its Cytotoxic Activities against Breast and Colorectal Cancer Cells. J. Integr. Med. 17 (3), 155–160. doi:10.1016/j.jijim.2019.03.003

Chang, C.-C., Chen, W.-C., Ho, T.-F., Wu, H.-S., and Wei, Y.-H. (2011). Development of Natural Anti-tumor Drugs by Microorganisms. J. Biosci. Bioeng. 111 (5), 501–511. doi:10.1016/j.jbiosc.2010.12.026

Cheng, C., Sui, B., Wang, M., Hu, X., Shi, S., and Xu, P. (2020). Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy. Adv. Healthcare Mater. 9 (19), 2001128. doi:10.1002/adhm.202001128

Ding, Z., Sigdel, K., Yang, L., Liu, Y., Xuan, M., Wang, X., et al. (2020). Nanotechnology-based Drug Delivery Systems for Enhanced Diagnosis and Therapy of Oral Cancer. J. Mater. Chem. B 8 (38), 8781–8793. doi:10.1039/d0tb0997a

Dombi, S., and Shirote, P. (2021). Nanoencapsulated Phytochemicals for Targeting Cancer: A Review. Cdt 22 (4), 443–462. doi:10.2174/138945012199920101201455

Fan, L., Zhang, B., Xu, A., Shen, Z., Guo, Y., Zhao, R., et al. (2018). Carrier-Free, Pure Nanodrug Formed by the Self-Assembly of an Anticancer Drug for Cancer Immune Therapy. Mol. Pharmaceutics 15 (6), 2466–2476. doi:10.1021/acs.molpharmaceut.8b00444

Fumagalli, G., Marucci, C., Christodoulou, M. S., Stella, B., Dosio, F., and Passarella, D. (2016). Self-assembly Drug Conjugates for Anticancer Treatment. Drug Discov. Today 21 (8), 1321–1329. doi:10.1016/j.drudis.2016.06.018

Guo, J., Ma, X., Zhang, L., Yan, J., Cui, H., Zhang, Y., et al. (2020). Self-Assembled Disulphide Bond Bearing Paclitaxel-Camptothecin Prodrug Nanoparticle for Lung Cancer Therapy. Pharmaceuticals 12 (12), 1169. doi:10.3390/pharmaceutics12121169

Guo, Y., Hu, J., and Ju, Y. (2016). Supramolecular Self-Assembly Based on Natural Small Molecules. Acta Chim. Sinica 74 (4), 312. doi:10.6023/ai6010016

Gigliobianco, M., Casadidio, C., Censi, R., and Di Martino, P. (2018). Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability. Pharmaceuticals 10 (3), 134. doi:10.3390/pharmaceutics10030134

Giannone, A., and Tomomonaro, G. (2019). Curcumin and Cancer. Nutrients 11 (10), 2376. doi:10.3390/nu11102376

Guo, J. L., Han, T., Bao, L., Li, X.-M., Ma, J. Q., and Tang, L. P. (2019). Ursolic Acid Promotes the Apoptosis of Cervical Cancer Cells by Regulating Endoplasmic Reticulum Stress. J. Obstet. Gynaecol. Res. 45 (4), 877–881. doi:10.1111/jog.13919

Guo, Y., Liu, H., Xiao, H., Yuan, M., Liu, Y., Seddafi, V., et al. (2021). Self-assembled Camptothecin Derivatives - Curcuminoids Conjugate for Combinatorial Chemo-Photodynamic Therapy to Enhance Anti-tumor Efficacy. J. Photochem. Photobiol. B: Biol. 215, 112124. doi:10.1016/j.jphotobiol.2021.112124

Hashizume, M., and Tsugawa, K. (2004). Robotic Surgery and Cancer: the Present State, Problems and Future Vision. Jpn. J. Clin. Oncol. 34 (5), 227–237. doi:10.1093/jjco/hyh053

Hu, S., Yu, X., Meng, L., Huang, L., and Sun, H. (2018). Curcumin Inhibits Proliferation and Promotes Apoptosis of Breast Cancer Cells. Exp. Ther. Med. 16 (2), 1266–1272. doi:10.3892/etm.2018.6345

Karaozmoglu, S., Zhou, M., Shi, B., Zhang, X., Williams, G. R., and Chen, X. (2021). Carrier-free Nanodrugs for Safe and Effective Cancer Treatment. J. Controlled Release 329, 805–832. doi:10.1016/j.jconrel.2020.10.014

Kartal-Yandim, M., Adan-Gokbulut, A., and Baran, Y. (2016). Molecular Mechanisms of Drug Resistance and its Reversal in Cancer. Crit. Rev. Bioeng. 36 (4), 716–726. doi:10.3109/07388551.2015.1015957

Khwaza, V., Oyedeji, O. O., and Aderibigbe, B. A. (2020). Ursolic Acid-Based Derivatives as Potential Anti-cancer Agents: An Update. IJMS 21 (16), 5920. doi:10.3390/ijms21165920

Kim, B., Park, J.-E., Im, E., Cho, Y., Lee, J., Lee, H.-J., et al. (2021). Recent Advances in Nanotechnology with Nano-Phytochemicals: Molecular Mechanisms and Clinical Implications in Cancer Progression. IJMS 22 (7), 3571. doi:10.3390/ijms22073571

Klein, C. A. (2020). Cancer Progression and the Invisible Phase of Metastatic Colonization. Nat. Rev. Cancer 20 (11), 681–694. doi:10.1038/s41568-020-00306-6

Kumar, A., and Jaitak, V. (2019). Natural Products as Multidrug Resistance Modulators in Cancer. Eur. J. Med. Chem. 176, 268–291. doi:10.1016/j.ejmech.2019.05.027

Lan, J.-S., Qin, Y.-H., Liu, L., Zeng, R.-F., Yang, Y., Wang, K., et al. (2021). A Carrier-free Folate Receptor-Targeted Ursolic Acid/Methotrexate Nanodelivery System for Synergetic Anticancer Therapy. IJn 16, 1775–1787. doi:10.2147/IJN.S287806

Li, L., Cui, H., Li, T., Qi, J., Chen, H., Gao, F., et al. (2020a). Synergistic Effect of Berberine-Based Chinese Medicine Assembled Nanostructures on Diarrhea-Predominant Irritable Bowel Syndrome In Vivo. Front. Pharmacol. 11, 1210. doi:10.3389/fphar.2020.01210

Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., et al. (2016). Overcoming ABC Transporter-Mediated Multidrug Resistance: Molecular Mechanisms and Novel Therapeutic Drug Strategies. Drug Resist. Updates 27, 14–29. doi:10.1016/j.drup.2016.05.001

Li, X., Yu, N., Li, J., Bai, J., Ding, D., Tang, Q., et al. (2020b). Novel “Carrier-free” Nanotheranostic Delivery Systems with the Synergistic Antitumor Effect of Paclitaxel and Tandetradine through the Enhancement of Mitochondrial Apoptosis. ACS Appl. Mater. Inter. 12 (9), 10996–11006. doi:10.1021/acsami.9b17363

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

ACKNOWLEDGMENTS

We wish to acknowledge Jiamusi University, and our corresponding author JD.
Li, Y.-J., Le, Y.-H., Yao, N., Wang, C.-R., Hu, N., Ye, W.-C., et al. (2017). Autophagy and Multidrug Resistance in Cancer. Chin. J. Cancer 36 (1), 52. doi:10.1186/s12557-017-0219-2

Li, Y.-J., Wu, J.-Y., Wang, J.-M., Hu, X.-B., Cai, J.-X., and Xiang, D.-X. (2020c). Geminicatide Loaded Autologous Exosomes for Effective and Safe Chemotherapy of Pancreatic Cancer. Acta Biomater. 101, 519–530. doi:10.1016/j.actbio.2019.10.022

Liao, Q., Yang, W., Jia, Y., Chen, X., Gao, Q., and Bi, K. (2005). LC-MS Determination and Pharmacokinetic Studies of Ursolic Acid in Rat Plasma after Administration of the Traditional Chinese Medicinal Preparation Lu-Ying Extract. Yakugaku Zasshi 125 (6), 509–515. doi:10.1248/yakuzasshi.125.509

Li, H., Yuan, M., Liu, Y., Guo, Y., Xiao, H., Guo, L., et al. (2021). Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy. Jpn J. Cancer Res. 116, 2487–2499. doi:10.2177/jnjc.2021.10.032

Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., et al. (2020). PI3K/AKT Pathway as a Key Link Modulates the Multidrug Resistance of Cancers. Cell Death Dis 11 (9), 797. doi:10.1038/s41419-020-02998-6

Ma, R., Wang, Z., Yan, L., Chen, X., and Zhu, G. (2014). Novel Pt-Loaded Layered Nanocrystals for Dissolution Rate and Bioavailability Enhancement: In vitro Anticancer Activity. J. Pharmaceutics Biopharmaceutics Therapies in Cancer: Drug Nanocarriers, the Future of Chemotherapy. doi:10.1039/c4tb00645c

Mei, H., Cai, S., Huang, D., Gao, H., Cao, J., and He, B. (2022). Carrier-free Nanodrugs with Efficient Drug Delivery and Release for Cancer Therapy: From Intrinsic Physicochemical Properties to External Modification. Bioactive Mater. 8, 220–240. doi:10.1016/j.bioactmat.2021.06.035

More, M. P., Pardeshi, S. R., Pardeshi, C. V., Sonawane, G. A., Shinde, M. N., Deshmukh, P. K., et al. (2021). Recent Advances in Phytochemical-Based Nano-Formulation for Drug-Resistant Cancer. Med. Drug Discov. 10, 100082. doi:10.1016/j.medidd.2021.100082

Pérez-Herrero, E., and Fernández-Medarde, A. (2015). Advanced Targeted Therapies in Cancer: Drug Nanocarriers, the Future of Chemotherapy. Eur. J. Pharmaceutics Biopharmaceutics 93, 52–79. doi:10.1016/j.ejpb.2015.03.018

Pi, J., Liu, Z., Wang, H., Gu, X., Wang, S., Zhang, B., et al. (2016). Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size. Cdd 13 (8), 1358–1366. doi:10.2174/15760181366661307142757

Pricci, M., Girardi, B., Giorgio, F., Losurdo, G., Ierardi, E., and Di Leo, A. (2020). Curcumin and Colorectal Cancer: From Basic to Clinical Evidences. Int. J. Pharmaceutics 592, 1–17. doi:10.1016/j.ijpharm.2019.118663

Qin, S.-Y., Zhang, A.-Q., Cheng, S.-X., Rong, L., and Zhang, X.-Z. (2017). Drug Therapy. Chin. J. Cancer 36 (1), 52. doi:10.4103/0973-1482.106526

Rizwanullah, M., Amin, S., Mir, S. R., Fakhri, K. U., and Rizvi, M. M. A. (2018). Synthesis of Carrier-free Curcumin Nanodrugs for Light-Activated Breast Cancer Photodynamic Therapy. Colloids Surf. B: Biointerfaces 180, 313–318. doi:10.1016/j.colsurfb.2019.04.061

Shabgah, A. G., Zari

Siddiqui, I. A., and Mukhtar, H. (2010). Nanochemoprevention by Bioactive Food Components: a Perspective. Pharm. Res. 27 (6), 1054–1060. doi:10.1007/s11158-010-0087-9

Siegel, R. L., Miller, K. D., Fuchs, E. H., and Jemal, A. (2021). Cancer Statistics, 2021. CA. Cancer J. Clin. 71 (1), 7–33. doi:10.3322/caac.21654

Swain, S. M., Honig, S. F., Tefft, M. C., and Walton, L. (1995). A Phase II Trial of Paclitaxel (Taxol) as First Line Treatment in Advanced Breast Cancer. Invest. New Drugs 13 (3), 217–222. doi:10.1007/bf00873803

Song, J., Wang, Y., Song, Y., Chan, H., Bi, C., Yang, X., et al. (2014). Development and Characterisation of Ursolic Acid Nanocrystals without Stabiliser Having Improved Dissolution Rate and In Vitro Anticancer Activity. AAPS PharmSciTech 15 (1), 11–19. doi:10.1208/s12249-013-0028-0

Stavrovskaya, A. A. (2000). Cellular Mechanisms of Multidrug Resistance of Tumor Cells. Biochemistry (Moscow) 65 (1), 95–106.

Sun, M., Zhang, Y., He, Y., Xiong, M., Huang, H., Pei, S., et al. (2019). Green Synthesis of Carrier-free Curcumin Nanodrugs for Light-Activated Breast Cancer Photodynamic Therapy. Colloids Surf. B: Biointerfaces 180, 313–318. doi:10.1016/j.colsurfb.2019.04.061

Termini, D., Den Hartogh, D. J., Jaglanian, A., and Tsiiani, E. (2020). Curcumin against Prostate Cancer: Current Evidence. Biomolecules 10 (11), 1536. doi:10.3390/biom10111536

Torre, L. A., Siegel, R. L., Ward, E. M., and Jemal, A. (2016). Global Cancer Incidence and Mortality Rates and Trends- An Update. Cancer Epidemiol. Biomarkers Prev. 25 (1), 16–27. doi:10.1158/1055-9965.epi-15-0578

Wang, J. L., Wang, K. X., Han, T. L., Li, J. M., He, X., Rong, R. X., et al. (2020b). Antitumour Properties Based on the Self-assembly of Camptothecin and Carbamoylmethane Conjugates. Chem. Biol. Drug Des. 96 (2), 870–877. doi:10.1111/cbdd.13698

Wang, J., Zhao, H., Zhi, K., and Yang, X. (2020a). Exploration of the Natural Active Anticancer Compound for Breast Cancer Therapy. Cell Death Dis 11 (9). doi:10.1038/s41419-020-02998-6

Whiteside, G. M., and Grzybowski, B. (2002). Self-assembly at All Scales. Science 295 (5564), 2418–2421. doi:10.1126/science.1070821

Xu, Y., Huang, Y., Zhang, Y., Lu, W., Yu, J., and Liu, S. (2018). Carrier-free Janus Nano-Prodrug Based on Camptothecin and Gelinbinbine: Reduction-Triggered Drug Release and Synergistic In Vitro Antiproliferative Effect in Multiple Cancer Cells. Int. J. Nanomed. 58, 1–12. doi:10.1016/j.ijpharm.2018.09.041

Yang, H., Gu, S., Li, J., Jin, L., Xie, X., Luo, L., et al. (2021). Synthesis of boron Carboditride Nanosheets Using for Delivering Paclitaxel and Their Antitumor Activity. ACS Appl. Mater. Inter. 12 (6), 6827–6839. doi:10.1021/acsami.9b18443

Yin, R., Li, T., Tian, J. X., Xi, P., and Liu, B. H. (2018). Ursolic Acid, a Potential Anticancer Compound for Breast Cancer Therapy. Crit. Rev. Food Sci. Nutr. 58 (4), 568–574. doi:10.1080/10408389.2016.1203755

Zhang, J., Li, Y., An, F.-F., Zhang, X., Chen, X., and Lee, C.-S. (2015). Preparation and Size Control of Sub-100 Nm Pure Nanodrugs. Nano Lett. 15 (1), 313–318. doi:10.1021/nl503598u
Zhao, Y., Zhao, Y., Ma, Q., Zhang, H., Liu, Y., Hong, J., et al. (2020). Novel carrier-free nanoparticles composed of 7-ethyl-10-hydroxycamptothecin and chlorin e6: Self-assembly mechanism investigation and In Vitro/In Vivo evaluation. *Colloids Surf. B: Biointerfaces* 188, 110722. doi:10.1016/j.colsurfb.2019.110722

Zhu, L., and Chen, L. (2019). Progress in Research on Paclitaxel and Tumor Immunotherapy. *Cell Mol Biol Lett* 24, 40. doi:10.1186/s11658-019-0164-y

Zhu, L., Guo, Y., Qian, Q., Yan, D., Li, Y., Zhu, X., et al. (2020). Carrier-Free Delivery of Precise Drug-Chemogene Conjugates for Synergistic Treatment of Drug-Resistant Cancer. *Angew. Chem. Int. Ed.* 59 (41), 17944–17950. doi:10.1002/anie.202006895

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Copyright © 2021 Jiang, Fu, Zhang, Yu, Lu and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.